Research programme: asthma and inflammation therapeutics - AbbVie

Drug Profile

Research programme: asthma and inflammation therapeutics - AbbVie

Alternative Names: ABT-362

Latest Information Update: 24 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Class
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 18 inhibitors; Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase inhibitors; Janus kinase-2 inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Asthma; Immunological disorders; Inflammation

Most Recent Events

  • 21 Jan 2013 This programme is still in active development
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 21 Oct 2011 Preclinical development is ongoing for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top